The preclinical and clinical activity of aviscumine: A potential anticancer drug

European Journal of Cancer

Volumn 47, Issue 10, 2011, Pages 1450-1457

  Zwierzina, Heinz ^a   Bergmann, Lothar ^b   Fiebig, Heiner ^c   Aamdal, Steinar ^d   Schöffski, Patrick ^e   Witthohn, Klaus ^f   Lentzen, Hans ^f  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c CHARLES RIVER LABORATORIES   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f CYTAVIS BioPharma GmbH   (Germany)

Author keywords

Aviscumine; Cancer immunotherapy; Cancer therapy; CD75s; Recombinant mistletoe lectin; Ribosome inactivating proteins; Solid tumours

Indexed keywords

AVISCUMINE;

ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; CANCER PAIN; CANCER THERAPY; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; ERYTHEMA; FATIGUE; FEVER; GRANULOCYTOPENIA; HUMAN; HYPOKALEMIA; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; NAUSEA; NEUTROPENIA; NOCTURIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; URTICARIA; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; ESCHERICHIA COLI; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MICE; NEOPLASMS; PLANT EXTRACTS; PLANT PREPARATIONS; PROTEIN CONFORMATION; RATS; RECOMBINANT PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 2; SIALYLTRANSFERASES; TOXINS, BIOLOGICAL; VISCUM ALBUM;

EID: 79958810291     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.02.022     Document Type: Article

References (55)

1. T. Hajto, K. Hostanska, and H.J. Gabius Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients Cancer Res 49 1989 4803 4808 (Pubitemid 19213628)
2. J. Beuth, H.L. Ko, and H.J. Gabius Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients Clin Investig 70 1992 658 661
3. J. Kleijnen, and P. Knipshild Review of controlled trials in humans Phytomedicine 1 1994 225 260
4. G.S. Kienle, F. Berrino, and A. Büssing Mistletoe in cancer - a systematic review on controlled clinical trials Eur J Med Res 8 2003 109 119
5. J. Weis, H.H. Bartsch, and F. Hennies Complementary medicine in cancer patients: demand, patients' attitudes and psychological beliefs Onkologie 21 1998 144 149 (Pubitemid 28267633)
6. E. Ernst, and B.R. Cassileth How useful are unconventional cancer treatments? Eur J Cancer 35 1999 1608 1613 (Pubitemid 29454535)
7. M. Langer, B. Möckel, J. Eck, H. Zinke, and H. Lentzen Site-specific mutagenesis of mistletoe lectin: the role of RIP activity in apoptosis Biochem Biophys Res Commun 264 1999 944 948
8. Y. Endo, K. Tsurugi, and H. Franz The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes. The RNA N-glycosidase activity of the protein FEBS Lett 231 1988 378 380
9. J. Eck, M. Langer, and B. Möckel Cloning the mistletoe lectin gene and characterization of the recombinant A chain Eur J Biochem 264 1999 775 784 (Pubitemid 29437206)
10. J. Eck, M. Langer, and B. Möckel Characterization of recombinant and plant-derived mistletoe lectin and their B-chains Eur J Biochem 265 1999 788 797 (Pubitemid 29489012)
11. S. Abuharbeid, J. Apel, and M. Sander Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells Biochem Biophys Res Commun 321 2004 403 412 (Pubitemid 39055761)
12. J. Müthing, M. Burg, and B. Möckel Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally alpha2-6-sialylated neolacto-series gangliosides Glycobiology 12 2002 485 497
13. J. Müthing, I. Meisen, and P. Bulau Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues Biochemistry 43 2004 2996 3007 (Pubitemid 38352250)
14. J.C. Zimring, S.B. Levery, and B. Kniep CD75s is a marker of murine CD8(+) suppressor T cells Int Immunol 15 2003 1389 1399 (Pubitemid 37369332)
15. J.H. Marino, M. Hoffman, M. Meyer, and K.S. Miller Sialyltransferase mRNA abundances in B cells are strictly controlled, correlated with cognate lectin binding, and differentially responsive to immune signaling in vitro Glycobiology 14 2004 1265 1274 (Pubitemid 39585359)
16. J. Jenner, G. Kerst, R. Handgretinger, and I. Muller Increased alpha2,6-sialylation of surface proteins on tolerogenic, immature dendritic cells and regulatory T cells Exp Hematol 34 2006 1212 1218
17. J.E. Arends, F.J. Bot, I.A. Gisbertz, and H.C. Schouten Expression of CD10, CD75 and CD43 in MALT lymphoma and their usefulness in discriminating MALT lymphoma from follicular lymphoma and chronic gastritis Histopathology 35 1999 209 215 (Pubitemid 29468954)
18. G.E. Marti, V. Zenger, and N.E. Caproaso Antigenic expression of B-cell chronic lymphocytic leukemic lymphocytes Anal Quant Cytol Histol 11 1989 315 323 (Pubitemid 19274020)
19. S. Lin, W. Kemmner, S. Grigull, and P.M. Schlag Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells Exp Cell Res 276 2002 101 110 (Pubitemid 34948355)
20. F. Dall 'Olio, M. Chiricolo, and C. Ceccarelli β-Galactoside α2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with sambucus nigra agglutinin Int J Cancer 88 2000 58 65
21. Skupin E. Bindungsverhalten des Rekombinanten Mistellektins, rViscumin, und der Monoklonalen Antikörper B72.3 und LN-1 in Normal- und Tumorgeweben: Eine Semiquantitative und Vergleichende Studie. Thesis. Köln, Germany: Universität zu Köln; 2006.
22. G.O. Elpek, T. Gelen, and G. Karpuzoglu Clinicopathologic evaluation of CDw75 antigen expression in colorectal adenocarcinomas Pathol Oncol Res 8 2002 175 179
23. G.O. Elpek, T. Gelen, G. Karpuzoglu, T. Karpuzoglu, and N. Keles Clinicopathologic evaluation of CDw75 antigen expression in patients with gastric carcinoma J Pathol 193 2001 169 174 (Pubitemid 32118127)
24. Y. Cao, A. Merling, P.R. Crocker, R. Keller, and R. Schwartz-Albiez Differential expression of beta-galactoside alpha2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma Lab Invest 82 2002 1515 1524 (Pubitemid 35332910)
25. M. Hedlund, E. Ng, A. Varki, and N.M. Varki Alpha 2-6-linked sialic acids on N-glycans modulate carcinoma differentiation in vivo Cancer Res 68 2008 388 394 (Pubitemid 351380065)
26. K. Blonski, U. Schumacher, and I. Burkholder Binding of recombinant mistletoe lectin (Aviscumine) to resected human adenocarcinoma of the lung Anticancer Res 25 2005 3303 3307 (Pubitemid 41105204)
27. M. Langer, B. Möckel, J. Eck, H. Zinke, and H. Lentzen Site-specific mutagenesis of mistletoe lectin: the role of RIP activity in apoptosis Biochem Biophys Res Commun 264 1999 944 948
28. K. Hostanska, T. Hajto, and J. Fischer Selective modulation of phosphatidylserine exposure on subpopulations of human peripheral blood lymphocytes by a plant lectin, Viscum album agglutinin (VAA)-I and its recombinant form (rVAA) in vitro Cancer Detect Prev 23 1999 511 523 (Pubitemid 29536883)
29. K. Hostanska, V. Vuong, and S. Rocha Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation Br J Cancer 88 2003 1785 1792 (Pubitemid 36760425)
30. B. Möckel, T. Schwartz, and J. Eck Apoptosis and cytokine release are biological responses mediated by recombinant mistletoe lectin in vitro Eur J Cancer 33 Suppl. 5 1997 S35
31. B. Möckel, J. Eck, M. Langer, H. Zinke, and H. Lentzen Induction of apoptosis in human blood cells by natural and recombinant mistletoe lectin S. Bardocz, F.V. Nekrep, A. Pustztai, Effects of antinutrients on the nutritional value of legume diets 1998 COST 98 Programme Office for Official Publications of the EC Luxembourg 94 101
32. B. Möckel, M. Krohn, and A. Katzenmaier Mode of action of rML: triggering of specific signalling pathways is probably due to intra-cellular ribosome inactivation Eur J Cancer 35 Suppl. 5 1999 S17
33. A. Savoie, V. Lavastre, and M. Pelletier Activation of human neutrophils by the plant lectin Viscum album agglutinin-I: modulation of de novo protein synthesis and evidence that caspases are involved in induction of apoptosis J Leukoc Biol 68 2000 845 853
34. V. Lavastre, M. Pelletier, R. Saller, K. Hostanska, and D. Girard Mechanisms involved in spontaneous and Viscum album agglutinin-I-induced human neutrophil apoptosis: Viscum album agglutinin-I accelerates the loss of antiapoptotic Mcl-1 expression and the degradation of cytoskeletal paxillin and vimentin proteins via caspases J Immunol 168 2002 1419 1427 (Pubitemid 34094514)
35. H. Bantel, I.H. Engels, W. Voelter, K. Schulze-Osthoff, and S. Wesselborg Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis Cancer Res 59 1999 2083 2090 (Pubitemid 29217669)
36. A.M. Burger, U. Mengs, and B. Gerstmayer Recombinant mistletoe lectin (rViscumin, rML) is a potent anticancer agent in experimental murine and human tumour models in vivo Clin Cancer Res Suppl. 1999 3762s
37. B. Möckel, A. Burger, and R.J. Schultz Assessing the cancerostatic potency of rViscumin towards human tumor xenografts and cell lines in vitro Eur J Cancer 37 2001 21s
38. K. Wilhelm-Ogunbiyi, B. Möckel, and A. Burger rViscumin, a novel anticancer agent - preclinical and clinical development status Eur J Cancer 3 2001 5s
39. B. Möckel, K. Wilhelm-Ogunbiyi, and A. Burger Preclinical and clinical development of the novel anticancer agent rViscumin J Cancer Res Clin Oncol 128 2002 S139
40. M. Langer, B. Möckel, K. Wilhelm-Ogunbiyi, K. Witthohn, and H. Lentzen Antitumour activity of rViscumin in vitro and in vivo Onkologie 26 2003 394
41. B. Schaffrath, U. Mengs, and T. Schwarz Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice Anticancer Res 21 2001 3981 3987 (Pubitemid 34229273)
42. U. Mengs, U. Elsässer-Beile, and A.M. Burger Antitumoral effects of recombinant viscumin (rViscumin) in vivo Proc Am Assoc Cancer Res 41 2000 656
43. U. Elsässer-Beile, T. Ruhnau, N. Freudenberg, U. Wetterauer, and U. Mengs Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model Cancer 91 2001 998 1004
44. T. Hajto, K. Hostanska, and K. Weber Effect of recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo Nat Immun 16 1998 34 46 (Pubitemid 28499445)
45. T. Schwarz, U. Elsässer-Beile, and B. Möckel Recombinant mistletoe lectin: a non-immunosuppressive cytotoxic agent in vitro Eur J Cancer 35 1999 17s
46. B. Möckel, A.M. Burger, and K. Hostanska rViscumin (recombinant mistletoe lectin): in vitro effects and mode of action of a novel anticancer agent Proc Am Assoc Cancer Res 41 2000 655
47. U. Schumacher, S. Feldhaus, and U. Mengs Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice Cancer Lett 150 2000 171 175 (Pubitemid 30125851)
48. U. Mengs, K. Weber, H.J. Hamann, and S.J. Corney The toxicology of recombinant mistletoe lectin (rViscumin, rML), a novel anticancer agent Clin Cancer Res 5 1999 3823s
49. O. Galm, U. Fabry, T. Efferth, and R. Osieka Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression Cancer Lett 187 2002 143 151 (Pubitemid 35279343)
50. I. Siegle, P. Fritz, M. McClellan, S. Gutzeit, and T.E. Murdter Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells Anticancer Res 21 2001 2687 2691 (Pubitemid 33054442)
51. P. Schöffski, S. Riggert, and P. Fumoleau Phase I trial of aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer new drug development group Ann Oncol 15 2004 1816 1824 (Pubitemid 40017162)
52. P. Schöffski, I. Breidenbach, and J. Krauter Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours Eur J Cancer 41 2005 1431 1438 (Pubitemid 40826467)
53. L. Bergmann, S. Aamdal, and S. Marreaud Phase I trial of rViscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001) Eur J Cancer 44 2008 1657 1662
54. Otto T, Rübben H. Die Intravesikale Applikation von Rekombinantem Mistellektin (rViscumin) in der Behandlung von Markerläsionen oberflächlicher Harnblasenkarzinome (Ta/1. GI-II) - Klinische Phase I/II Studie; 2000.
55. M.A. Cheever Twelve immunotherapy drugs that could cure cancers Immunol Rev 222 2008 357 368 (Pubitemid 351430366)